164 related articles for article (PubMed ID: 38563697)
1. Positive Impact of a New Compressive Garment in Patients with Genital Lymphedema: OLYMPY Study.
Mestre S; Vignes S; Malloizel-Delaunay J; Abba S; Villet S; Picolet A; Vicaut E; Quéré I
Lymphat Res Biol; 2024 Apr; 22(2):138-146. PubMed ID: 38563697
[No Abstract] [Full Text] [Related]
2. Impact on Health-Related quality of life after wearing compression garment or not for six months in women with mild breast cancer-related arm lymphedema. A cross-sectional study.
Blom KY; Johansson KI; Nilsson-Wikmar LB; Klernäs PE; Brogårdh CB
Acta Oncol; 2023 May; 62(5):528-534. PubMed ID: 37211678
[TBL] [Abstract][Full Text] [Related]
3. Assessment of quality of life changes in patients with lower extremity lymphedema using an advanced pneumatic compression device at home.
Maldonado TS; Rokosh RS; Padberg F; Rotella V; Miller H; Nassiri N; Jacobowitz G; Berland T; Sadek M; Barfield ME
J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):745-752. PubMed ID: 33137494
[TBL] [Abstract][Full Text] [Related]
4. Adherence to Compression Garment Wear and Associated Factors Among Patients with Breast Cancer-Related Lymphedema: A Pilot Study from a Turkish Tertiary Center.
Erdinç Gündüz N; Şahin E; Dilek B; Ellidokuz H; Akalın E
Lymphat Res Biol; 2022 Dec; 20(6):665-670. PubMed ID: 35245100
[No Abstract] [Full Text] [Related]
5. Nighttime compression supports improved self-management of breast cancer-related lymphedema: A multicenter randomized controlled trial.
McNeely ML; Dolgoy ND; Rafn BS; Ghosh S; Ospina PA; Al Onazi MM; Radke L; Shular M; Kuusk U; Webster M; Campbell KL; Mackey JR
Cancer; 2022 Feb; 128(3):587-596. PubMed ID: 34614195
[TBL] [Abstract][Full Text] [Related]
6. Low-Intensity Resistance Training and Compression Garment in the Management of Breast Cancer-Related Lymphedema: Single-Blinded Randomized Controlled Trial.
Omar MTA; Gwada RFM; Omar GSM; El-Sabagh RM; Mersal AAE
J Cancer Educ; 2020 Dec; 35(6):1101-1110. PubMed ID: 31243692
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a novel night-time compression garment: a prospective observational study.
Bertsch T
Br J Community Nurs; 2018 Nov; 23(11):535-541. PubMed ID: 30398919
[TBL] [Abstract][Full Text] [Related]
8. Impact of seamless compression garments on limb functionality, comfort and quality of life.
Miller A
Br J Community Nurs; 2017 Oct; 22(Sup10):S26-S37. PubMed ID: 28961051
[TBL] [Abstract][Full Text] [Related]
9. An innovative flat-knit compression garment for lymphoedema patients led to better outcomes: a multicentre study.
Hirsch T; Arns H; Schleinitz J; Fiedler HW
J Wound Care; 2024 Apr; 33(4):220-228. PubMed ID: 38573905
[TBL] [Abstract][Full Text] [Related]
10. Ostomy Complications and Quality of Life of Ostomy Support Belt/Garment Wearers: A Web-Based Survey.
Pittman J; Colwell J; Mulekar MS
J Wound Ostomy Continence Nurs; 2022 Jan-Feb 01; 49(1):60-68. PubMed ID: 35040815
[TBL] [Abstract][Full Text] [Related]
11. Surgical versus Nonsurgical Management of Postmastectomy Lymphedema: A Prospective Quality of Life Investigation.
Darrach H; Yesantharao PS; Persing S; Kokosis G; Carl HM; Bridgham K; Seu M; Stifler S; Sacks JM
J Reconstr Microsurg; 2020 Oct; 36(8):606-615. PubMed ID: 32623705
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of night-time compression for breast cancer related lymphedema (LYNC): protocol for a multi-centre, randomized controlled efficacy trial.
McNeely ML; Campbell KL; Webster M; Kuusk U; Tracey K; Mackey J
BMC Cancer; 2016 Aug; 16():601. PubMed ID: 27491361
[TBL] [Abstract][Full Text] [Related]
13. Quality of life evaluation and lack of correlation with volumetric results after lymphovenous anastomoses in lymphedema therapy of the lower extremity.
Schiltz D; Kiermeier N; Müller K; Diesch ST; Wenzel C; Biermann N; Prantl L; Taeger CD
J Vasc Surg Venous Lymphat Disord; 2022 Mar; 10(2):436-444.e1. PubMed ID: 34352420
[TBL] [Abstract][Full Text] [Related]
14. Lymphedema Quality of Life Inventory (LyQLI)-Development and investigation of validity and reliability.
Klernäs P; Johnsson A; Horstmann V; Kristjanson LJ; Johansson K
Qual Life Res; 2015 Feb; 24(2):427-39. PubMed ID: 25633655
[TBL] [Abstract][Full Text] [Related]
15. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
Mezalek ZT; Feodor T; Chernukha L; Chen Z; Rueda A; Sánchez IE; Ochoa AJG; Chirol J; Blanc-Guillemaud V; Lohier-Durel C; Ulloa JH
Adv Ther; 2023 Nov; 40(11):5016-5036. PubMed ID: 37728696
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life Improvements in Patients with Lymphedema After Surgical or Nonsurgical Interventions with 1-Year Follow-Up.
Klernäs P; Johnsson A; Boyages J; Brorson H; Munnoch A; Johansson K
Lymphat Res Biol; 2020 Aug; 18(4):340-350. PubMed ID: 31808720
[No Abstract] [Full Text] [Related]
17. Complex physical therapy employing self-adjusting garment (ReadyWrap®) in breast cancer-related lymphedema cases in Brazilian women: a protocol for a randomized controlled trial.
da Silva JMP; Araújo RDD; da Silva Santos FC; Fabro EAN; de Mello Pinto MV; de Aguiar SS; Thuler LCS; Bergmann A
Trials; 2023 Aug; 24(1):549. PubMed ID: 37608354
[TBL] [Abstract][Full Text] [Related]
18. Manual lymphatic drainage for lymphedema following breast cancer treatment.
Ezzo J; Manheimer E; McNeely ML; Howell DM; Weiss R; Johansson KI; Bao T; Bily L; Tuppo CM; Williams AF; Karadibak D
Cochrane Database Syst Rev; 2015 May; 2015(5):CD003475. PubMed ID: 25994425
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.
Leppäpuska IM; Hartiala P; Suominen S; Suominen E; Kaartinen I; Mäki M; Seppänen M; Kiiski J; Viitanen T; Lahdenperä O; Vuolanto A; Alitalo K; Saarikko AM
J Plast Reconstr Aesthet Surg; 2022 Nov; 75(11):3938-3945. PubMed ID: 36151039
[TBL] [Abstract][Full Text] [Related]
20. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
